Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
about
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapyImpact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotypeAurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancerThe phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridolA Phase II Study of Flavopiridol in Patients With Previously Untreated Advanced Soft Tissue Sarcoma.Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial.Identification of Candidate Cyclin-dependent kinase 1 (Cdk1) Substrates in Mitosis by Quantitative Phosphoproteomics.Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.Inhibition of polo like kinase 1 in sarcomas induces apoptosis that is dependent on Mcl-1 suppressionAutophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model.Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.The p53 breast cancer tissue biomarker in Indian women.Enhancement of radiation effects by flavopiridol in uterine cervix cancer cells.Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets.Cyclin-dependent kinase inhibitors and the treatment of gastrointestinal cancers.Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.Different types of cell cycle- and apoptosis-related gene expressions alter in corticosteroid-, vincristine-, and melphalan-resistant u-266 multiple myeloma cell lines
P2860
Q21245716-EEBDE00C-EE42-4292-B518-298353E1B69DQ27334924-FEB19E16-19E5-4684-9380-07B16BB9BB9CQ30487026-B2F52164-3092-40FC-9A0C-28F128F5705AQ33387187-DBA28637-8F72-4FD8-AAF1-56D004C97268Q33739625-784E2A19-C66A-45D1-B51A-3AE014902BE4Q34096861-96CEF123-BC9C-4EFE-8E85-4DAD2E8B531DQ34214083-1BC55251-E903-4A4F-AF67-0B710BAFBD64Q35220471-71BCC9D2-4461-4E83-85E3-D73896ADB1F6Q35668911-A1E62138-B1F9-43C5-B3EE-3B531B803432Q35931388-D2E9F5F2-0024-4759-9A41-BB1303CF1CDAQ36004764-58B78356-AA57-444A-B383-90337F1D4D93Q36187896-117DD451-1C95-4D95-B105-B5DC4246E792Q36363971-5E1F4657-47AB-4608-AE7A-E4ED88CB1ED6Q36745599-C67E20AF-3171-417A-B28B-13C1BCE0F555Q36780701-EB7E5A43-DA04-4241-A467-F7BDDDE2ED52Q36922550-03A2757A-A1CC-4CD9-98FB-89747681C670Q37001622-A08F83AF-6A55-49E3-ACA6-31C7535E07D8Q37199458-13D52295-E3A3-45C4-8B0F-79E2D22B27CDQ37356294-BA97EBE6-418E-44FA-A815-C2D1F8DD6669Q37447008-6AB97C67-1202-4F75-801C-0A945C804832Q37723910-C95299D0-ECDF-471A-A2C0-14C8D810E292Q38369468-7468A54A-A5F6-4EF0-8DA2-865C16D09896Q39745964-267240E3-77A4-4460-AB53-548E1711028EQ41872421-868EBA6D-D0EB-4D9E-B4A4-7CE3638E7D3E
P2860
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Sequential dependent enhanceme ...... astric and breast cancer cells
@ast
Sequential dependent enhanceme ...... astric and breast cancer cells
@en
Sequential dependent enhanceme ...... astric and breast cancer cells
@nl
type
label
Sequential dependent enhanceme ...... astric and breast cancer cells
@ast
Sequential dependent enhanceme ...... astric and breast cancer cells
@en
Sequential dependent enhanceme ...... astric and breast cancer cells
@nl
prefLabel
Sequential dependent enhanceme ...... astric and breast cancer cells
@ast
Sequential dependent enhanceme ...... astric and breast cancer cells
@en
Sequential dependent enhanceme ...... astric and breast cancer cells
@nl
P2093
P1476
Sequential dependent enhanceme ...... astric and breast cancer cells
@en
P2093
Delohery TM
Schwartz GK
P304
P407
P577
1999-07-01T00:00:00Z